Safety and Effectiveness of Ciclesonide Nasal Spray in Patients with Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
Study identifier:BY9010/M1-404
ClinicalTrials.gov identifier:NCT00163501
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older
Medical condition
Perennial Allergic Rhinitis
Phase
Phase 3
Healthy volunteers
No
Study drug
Ciclesonide
Sex
All
Actual Enrollment
600
Study type
Interventional
Age
12 Years +
Date
Study Start Date: 01 Dec 2003
Primary Completion Date: 01 Apr 2005
Study Completion Date: 01 Apr 2005
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
